WASHINGTON (Reuters) – U.S. health regulators’ decision on whether to approve Pfizer and BioNTech’s COVID-19 vaccine for children ages 5 to 11 could spill over into November if needed, the nation’s top u.s. infectious disease official said on Wednesday.
Dr. Anthony Fauci, asked about Wall Street Journal reporting that expanded approval may not come next month depending on when the companies file a formal application, said the Food and Drug Administration was working expeditiously and that “if it goes into November, that’s because it’s necessary.”
(Reporting by Susan Heavey)
